Stick With Traditional Opioid Formulations for Most Patients

May 2014

The Zohydro controversy will lead to more interest in "abuse-deterrent" opioid formulations.

Zohydro is the new long-acting hydrocodone for chronic, severe pain. It's controversial because it's NOT an abuse-deterrent formulation...despite concerns about its abuse potential.

Abuse-deterrent formulations aren't required by FDA...but are being promoted in an effort to reduce prescription opioid abuse.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote